Question explored with the scientific record
what is ivermectin effective at treating — beyond parasites and river blindness — both alone and in combination with other drugs?
Ivermectin's non-parasitic record is thin: the best evidence is for head lice, and the COVID-19 case has largely collapsed.
The strongest non-parasitic signal in these records is head lice. A household-randomized trial found oral ivermectin at 400 µg/kg, given twice a week apart, left 95.2% of patients lice-free by day 15 versus 85.0% on malathion lotion, with no difference in side effects [8]. A single 200 µg/kg dose cleared only 6 of 26 people, so the dose and repeat matter [8]. A placebo-controlled trial in Sierra Leonean children found a 46% reduction in lice prevalence [9].
For COVID-19, the largest synthesis is the most damning: 40 randomized trials and 23,243 participants found no significant benefit on infection, death, or adverse events [1]. The 2026 meta-analysis of 23 trials (12,345 people) likewise found no significant improvement in viral clearance, hospital stay, or symptom resolution [4]. The positive studies were mostly observational or small: an Abuja cohort reported faster clearance and no deaths versus four in the non-ivermectin arm, but it was non-randomized and enrolled patients in different variant waves [2]. A Bangladesh study found earlier clearance with ivermectin plus doxycycline, but it had no randomization and a PCR endpoint [3]. The one randomized combination trial, ivermectin plus doxycycline, did shorten recovery (median 7 vs 9 days) and cut progression, but it was single-center and could not separate the two drugs [5].
| Condition | Best design | Result | Confidence |
|---|---|---|---|
| Head lice | Household RCT, 400 µg/kg x2 | 95.2% vs 85.0% lice-free day 15 [8] | Moderate |
| COVID-19 treatment | 40 RCTs, 23,243 people | No benefit on death or infection [1] | High (null) |
| COVID-19, IVM+doxycycline | Single RCT, 400 people | 7 vs 9 days to recovery [5] | Low |
| Scabies | Cochrane review | No large difference vs permethrin [8] | Low |
The safety side is not clean. A 2026 pharmacovigilance analysis of 1,421 reports flagged signals for encephalopathy and toxic encephalopathy, with higher reporting odds than albendazole [6]. Voluntary reporting systems detect a fraction of real events, so this is a signal, not a rate. A separate case series found 28 serious neurological events after non-onchocerciasis use, three recurring on re-exposure [7].
My call: use it for lice at the studied dose, treat the COVID-19 claims as failed, and do not expect it to do what the marketing says. Confidence: moderate for lice, high that the COVID-19 benefit claims do not hold.
Sources used 9
-
The role of ivermectin in the prevention and treatment of SARS-CoV-2 infection: a meta-analysis of randomized controlled trials
In 40 RCTs (23,243 participants), ivermectin showed no statistically significant preventive or therapeutic benefit for SARS-CoV-2 infection, with no significant effects on infection rate, mortality, adverse events, or most secondary outcomes.
DOI: 10.1186/s12879-026-13195-9 -
A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality
In a non-randomized Abuja cohort, ivermectin-based COVID-19 treatment was associated with faster viral clearance, shorter time to discharge, and lower mortality than non-ivermectin regimens after propensity matching.
DOI: 10.9734/jpri/2022/v34i44a36328 -
Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients
A prospective comparative study in Bangladesh comparing ivermectin with doxycycline versus hydroxychloroquine with azithromycin in 400 mild-to-moderate COVID-19 patients, finding earlier viral clearance with ivermectin+doxycycline and overall safety in both regimens, though limi…
DOI: 10.3329/jbcps.v38i0.47514 -
Repurposing Anthelmintic Drugs for COVID-19 Treatment: A Comprehensive Meta-Analysis of Randomized Clinical Trials on Ivermectin and Mebendazole
An up-to-date meta-analysis of 23 randomized trials (n = 12,345) evaluating ivermectin and mebendazole for COVID-19 found no statistically significant improvement in viral clearance, hospitalization duration, or symptom resolution overall, although some individual studies sugges…
DOI: 10.3390/antibiotics14050459 -
Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial
Combining ivermectin with doxycycline shortened time to clinical recovery and reduced disease progression and viral persistence in adults with mild-to-moderate COVID-19 compared with placebo.
DOI: 10.1177/03000605211013550 -
Elucidating adverse drug reactions and underlying molecular mechanisms of ivermectin through pharmacovigilance and multi-omics analysis
FAERS pharmacovigilance found ivermectin safety signals in eye, nervous system, and general disorders, with network toxicology nominating EGFR, ERBB2, TGFB1, PIK3CA, and HSPG2 as candidate toxicity targets.
DOI: 10.3389/fcimb.2026.1938550 -
Serious Neurological Adverse Events after Ivermectin—Do They Occur beyond the Indication of Onchocerciasis?
Serious neurological adverse events were reported in 28 VigiBase cases taking ivermectin for non-onchocerciasis indications, including three with recurrence on rechallenge, suggesting a possible rare causative role beyond onchocerciasis and loiasis.
DOI: 10.4269/ajtmh.17-0042 -
High-dose ivermectin in malaria and other parasitic diseases: a new step in the development of a neglected drug
Published trials indicate that high-dose oral ivermectin (300–400 µg/kg) is effective and well tolerated in malaria and difficult-to-treat head lice, supporting evaluation of higher doses in severe scabies.
DOI: 10.1051/parasite/2018039 -
Impact of ivermectin on illness and disability associated with onchocerciasis
Mass ivermectin distribution over 15 years is safe and has substantially reduced onchocercal microfilarial loads, transmission, blindness risk, and skin disease disability.
DOI: 10.1111/j.1365-3156.2004.01213.x